{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Brivanib_Alaninate",
  "nciThesaurus": {
    "casRegistry": "649735-63-7",
    "chebiId": "",
    "chemicalFormula": "C22H24FN5O4",
    "definition": "The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.",
    "fdaUniiCode": "U2Y5OFN795",
    "identifier": "C53397",
    "preferredName": "Brivanib Alaninate",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C1742",
      "C1967"
    ],
    "synonyms": [
      "BMS 582664",
      "BMS-582664",
      "BRIVANIB ALANINATE",
      "Brivanib Alaninate",
      "brivanib alaninate"
    ]
  }
}